Former i3 CEO Bilawsky tapped to lead Precision Health Economics

Friday, October 19, 2012 02:55 PM

Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.

Bilawsky served as CEO of the i3 division of UnitedHealth Group for more than eight years. He brings more than a quarter century of pharmaceutical and contract research experience and has been instrumental in helping several organizations achieve global leadership positions.

"We have a slate of brilliant researchers and analysts who are in demand by our clients throughout the healthcare industry and in the highest levels of government,” said Darius Lakdawalla, co-founder of PHE. “We need a proven leader with the business acumen to refine our strategy while creating and managing a platform for growth.  Glenn is that person."

PHE was formed in 2005 by Tomas Philipson, Dana Goldman and Lakdawalla, all renowned health economists from elite universities. Their goal was to use sophisticated, data-driven analysis tailored to each client's strategic needs, and to improve public policy through insightful, issue-driven research. Today the firm has three offices across the country and a network of affiliated academic economists and clinicians from the world's leading universities. Bilawsky plans to expand the national footprint, then move into Europe and Asia.

"This is a rare opportunity to step in at this stage to help shape PHE's growth and provide the strategic and operational platform to fuel its expansion," said Bilawsky. "The cost of healthcare is a global concern. There is a rapidly growing need for information and guidance from a trusted source for all constituents: payers; providers; and manufacturers of pharma, biotechnology, medical device and diagnostic products. I have the good fortune to build on PHE's many assets, which include its preeminent expertise and brand reputation in both the total healthcare and government markets. The PHE team and its network have no peer in the industry."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs